Atlas Trials

A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY

Clinical trial NCT07019545 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07019545
Sponsor
Hellenic Society of Hematology
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Immune Thrombocytopenia (ITP)
Start date
2025-06-20
Primary completion
2026-06-20
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.